Linking clinicians and lab researchers for gene discovery: New publication on the Canadian Rare Disease Models and Mechanisms network
Over 70% of rare diseases are genetic in origin, but our understanding of the biological function of the 19,000 genes in the human genome is still often inadequate to reliably predict whether a defect in a particular gene is likely to cause a specific disease. Now that sequencing technologies that look for defects across the whole genome are becoming commonplace in diagnostics, clinicians attempting to diagnose their patients increasingly encounter the situation where they suspect a certain defect of being causative of the patient’s disease but do not have sufficient biological evidence to provide a certain diagnosis. To get from a “suspicion” about a defect in a gene not previously associated with a disease to biological proof of its effect requires extensive further research in cell and animal models, and this step is frequently one that the original clinician does not have the resources to perform.
The Canadian Rare Diseases Models and Mechanisms (RDMM) network was established to connect clinicians discovering new disease genes with Canadian scientists able to study equivalent genes and pathways in model organisms. It has developed a registry of more than 500 Canadian model organism scientists, representing expertise for over 7,500 human genes. To date, it has made 85 connections between clinicians and the scientists studying their genes of interest and has provided funding for 105 projects. These collaborations help confirm variant pathogenicity and unravel the molecular mechanisms of rare diseases, and also test novel therapies and lead to long-term collaborations. NMD4C collaborates with the RDMM network to ensure that neuromuscular clinicians with a gene of interest have the opportunity to seek scientists with the relevant expertise, as well as enabling NMD scientists to register with the network in order to facilitate future collaborations.
The story of the RDMM to date is nicely summarised in this new article by Boycott et al in the American Journal of Human Genetics:
Boycott KM, Campeau PM, Howley HE, Pavlidis P, Rogic S, Oriel C, Berman JN, Hamilton RM, Hicks GG, Lipshitz HD, Masson JY, Shoubridge EA, Junker A, Leroux MR, McMaster CR, Michaud JL, Turvey SE, Dyment D, Innes AM, van Karnebeek CD, Lehman A, Cohn RD, MacDonald IM, Rachubinski RA, Frosk P, Vandersteen A, Wozniak RW, Pena IA, Wen XY, Lacaze-Masmonteil T, Rankin C, Hieter P.
The Canadian Rare Diseases Models and Mechanisms (RDMM) Network: Connecting Understudied Genes to Model Organisms
Am J Hum Genet. 2020 Feb 6;106(2):143-152. doi: 10.1016/j.ajhg.2020.01.009.
PMID: 32032513
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.